275 related articles for article (PubMed ID: 29673809)
41. Combination molecular therapies for type 1 spinal muscular atrophy.
Harada Y; Rao VK; Arya K; Kuntz NL; DiDonato CJ; Napchan-Pomerantz G; Agarwal A; Stefans V; Katsuno M; Veerapandiyan A
Muscle Nerve; 2020 Oct; 62(4):550-554. PubMed ID: 32710634
[TBL] [Abstract][Full Text] [Related]
42. Nusinersen does not improve lung function in a cohort of children with spinal muscular atrophy - A single-center retrospective study.
Heitschmidt L; Pichlmaier L; Eckerland M; Steindor M; Olivier M; Fuge I; Kölbel H; Hirtz R; Stehling F
Eur J Paediatr Neurol; 2021 Mar; 31():88-91. PubMed ID: 33711791
[TBL] [Abstract][Full Text] [Related]
43. Intrathecal administration of nusinersen in adult and adolescent patients with spinal muscular atrophy and scoliosis: Transforaminal versus conventional approach.
Bortolani S; Stura G; Ventilii G; Vercelli L; Rolle E; Ricci F; Bergui M; Mongini T
Neuromuscul Disord; 2019 Oct; 29(10):742-746. PubMed ID: 31604650
[TBL] [Abstract][Full Text] [Related]
44. Nusinersen for the treatment of spinal muscular atrophy.
Chiriboga CA
Expert Rev Neurother; 2017 Oct; 17(10):955-962. PubMed ID: 28884620
[TBL] [Abstract][Full Text] [Related]
45. Intrathecal nusinersen treatment for SMA in a dedicated neuromuscular clinic: an example of multidisciplinary and integrated care.
Sansone VA; Albamonte E; Salmin F; Casiraghi J; Pirola A; Bettinelli M; Rao F; Mancini L; Tovaglieri N; Fedeli F; Stoia P; Heinen M; Cozzi V; Carraro E; Lunetta C; Di Bari A; Mercuri E;
Neurol Sci; 2019 Feb; 40(2):327-332. PubMed ID: 30430317
[TBL] [Abstract][Full Text] [Related]
46. Outcomes in type 1 spinal muscular atrophy on nusinersen: A single center experience.
Kaltman J; Kern-Smith E; Zhang C; Figueroa J; Ritchey M; Razdan R; Verma S
Clin Neurophysiol; 2020 Dec; 131(12):2793-2794. PubMed ID: 33130439
[No Abstract] [Full Text] [Related]
47. Preliminary Safety and Tolerability of a Novel Subcutaneous Intrathecal Catheter System for Repeated Outpatient Dosing of Nusinersen to Children and Adults With Spinal Muscular Atrophy.
Strauss KA; Carson VJ; Brigatti KW; Young M; Robinson DL; Hendrickson C; Fox MD; Reed RM; Puffenberger EG; Mackenzie W; Miller F
J Pediatr Orthop; 2018; 38(10):e610-e617. PubMed ID: 30134351
[TBL] [Abstract][Full Text] [Related]
48. [Spinal muscular atrophy treated with nusinersen].
Boesen MS; Albrechtsen S; Born AP
Ugeskr Laeger; 2019 Jan; 181(2):. PubMed ID: 30618374
[TBL] [Abstract][Full Text] [Related]
49. Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience.
Messina S; Pane M; Sansone V; Bruno C; Catteruccia M; Vita G; Palermo C; Albamonte E; Pedemonte M; Bertini E; Binetti L; Mercuri E;
Neuromuscul Disord; 2017 Dec; 27(12):1084-1086. PubMed ID: 29132728
[No Abstract] [Full Text] [Related]
50. Needleless inhaled anesthesia with sevoflurane: Advantages of a simplified approach for children with spinal muscular atrophy undergoing intrathecal administration of nusinersen.
Salerno A; Picconi E; Genovese O; Piastra M; Pulitanò SM; Tosi F; Mancino A; Pane M; De Sanctis R; Carlini D; Mercuri EM; Conti G
Paediatr Anaesth; 2023 Apr; 33(4):282-290. PubMed ID: 36636888
[TBL] [Abstract][Full Text] [Related]
51. Spinal adhesive arachnoiditis in an adult patient with spinal muscular atrophy type 3 treated with intrathecal therapy.
Ubysz J; Koszewicz M; Bladowska J; Budrewicz S
BMC Neurol; 2024 Jan; 24(1):43. PubMed ID: 38267835
[TBL] [Abstract][Full Text] [Related]
52. Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen.
Sansone VA; Pirola A; Albamonte E; Pane M; Lizio A; D'Amico A; Catteruccia M; Cutrera R; Bruno C; Pedemonte M; Messina S; Rao F; Roma E; Salmin F; Coratti G; Di Bari A; De Sanctis R; Pera CM; Sframeli M; Piastra M; Macagno F; Vita G; Bertini E; Mercuri E
J Pediatr; 2020 Apr; 219():223-228.e4. PubMed ID: 32035635
[TBL] [Abstract][Full Text] [Related]
53. Nusinersen for older patients with spinal muscular atrophy: A real-world clinical setting experience.
Veerapandiyan A; Eichinger K; Guntrum D; Kwon J; Baker L; Collins E; Ciafaloni E
Muscle Nerve; 2020 Feb; 61(2):222-226. PubMed ID: 31773738
[TBL] [Abstract][Full Text] [Related]
54. Two Years of Improved Neurological Function With Nusinersen in a 48-Year-Old Patient With Spinal Muscular Atrophy Type 3.
Shah JS; Rubin DI; Dimberg EL; Owens CR; Gicalone AR; De Oliveira G; Oskarsson BE
Neurologist; 2020 Sep; 25(5):141-143. PubMed ID: 32925486
[TBL] [Abstract][Full Text] [Related]
55. Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy.
Paton DM
Drugs Today (Barc); 2017 Jun; 53(6):327-337. PubMed ID: 28799578
[TBL] [Abstract][Full Text] [Related]
56. Nusinersen for SMA: expanded access programme.
Farrar MA; Teoh HL; Carey KA; Cairns A; Forbes R; Herbert K; Holland S; Jones KJ; Menezes MP; Morrison M; Munro K; Villano D; Webster R; Woodcock IR; Yiu EM; Sampaio H; Ryan MM
J Neurol Neurosurg Psychiatry; 2018 Sep; 89(9):937-942. PubMed ID: 29549190
[TBL] [Abstract][Full Text] [Related]
57. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps.
Gidaro T; Servais L
Dev Med Child Neurol; 2019 Jan; 61(1):19-24. PubMed ID: 30221755
[TBL] [Abstract][Full Text] [Related]
58. Ultrasound-guided nusinersen administration for spinal muscular atrophy patients with severe scoliosis: an observational study.
Zhang J; Cui X; Chen S; Dai Y; Huang Y; Zhang S
Orphanet J Rare Dis; 2021 Jun; 16(1):274. PubMed ID: 34120632
[TBL] [Abstract][Full Text] [Related]
59. Reader response: Evidence in focus: Nusinersen use in spinal muscular atrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Takanashi JI; Takase N
Neurology; 2019 Sep; 93(10):464. PubMed ID: 31477617
[No Abstract] [Full Text] [Related]
60. Nusinersen treatment response markers.
Fyfe I
Nat Rev Neurol; 2022 Jul; 18(7):381. PubMed ID: 35676372
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
